Panagiotis Pavlou - Lavipharm Group Director
| LAVI Stock | EUR 0.71 0.01 1.39% |
Insider
Panagiotis Pavlou is Group Director of Lavipharm SA
| Phone | 30 210 66 91 000 |
| Web | https://www.lavipharm.gr |
Lavipharm Management Efficiency
The company has return on total asset (ROA) of 0.0403 % which means that it generated a profit of $0.0403 on every $100 spent on assets. This is way below average. Lavipharm's management efficiency ratios could be used to measure how well Lavipharm manages its routine affairs as well as how well it operates its assets and liabilities.Lavipharm SA has accumulated 40.54 M in total debt. Lavipharm SA has a current ratio of 1.26, suggesting that it may not be capable to disburse its financial obligations in time and when they become due. Debt can assist Lavipharm until it has trouble settling it off, either with new capital or with free cash flow. So, Lavipharm's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Lavipharm SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Lavipharm to invest in growth at high rates of return. When we think about Lavipharm's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Samonakis Nikolaos | Profile Systems Software | N/A | |
| Andreas Karelias | Karelia Tobacco | N/A | |
| Charalampos Stasinopoulos | Profile Systems Software | 61 | |
| Fotini Kyrlidou | Thrace Plastics Holding | N/A | |
| Marianna Stengou | Technical Olympic SA | 45 | |
| Aristodimos Dimitriadis | Hellenic Telecommunications Org | 58 | |
| Eirini Nikolaidi | Hellenic Telecommunications Org | 54 | |
| Konstantinos Chalioris | Thrace Plastics Holding | 61 | |
| Santoukas Zafeirios | Profile Systems Software | N/A | |
| Lambros Apostolopoulos | Thrace Plastics Holding | N/A | |
| Elias Georgantas | Intertech SA Inter | N/A | |
| Dimitrios Malamos | Thrace Plastics Holding | 47 | |
| Georgios Alevizopoulos | Karelia Tobacco | N/A | |
| Michael Tsamaz | Hellenic Telecommunications Org | 64 | |
| Charalampos Mazarakis | Hellenic Telecommunications Org | 59 | |
| Michael Psarros | Thrace Plastics Holding | N/A | |
| Vasiliki Tsoumelea | Karelia Tobacco | N/A | |
| Theodora Tsotaki | Intertech SA Inter | 57 | |
| Evangelia Sideri | Thrace Plastics Holding | N/A | |
| Konstantinos Stengos | Technical Olympic SA | 86 | |
| George CIA | Karelia Tobacco | 58 | |
Management Performance
| Return On Asset | 0.0403 |
Lavipharm SA Leadership Team
Elected by the shareholders, the Lavipharm's board of directors comprises two types of representatives: Lavipharm inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lavipharm. The board's role is to monitor Lavipharm's management team and ensure that shareholders' interests are well served. Lavipharm's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lavipharm's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Katerina Fragioudakis, Head Chairman | ||
| Vassilis Baloumis, Group CFO | ||
| Panagiotis Giannouleas, COO Mang | ||
| Spyridon Fotinos, Chief Officer | ||
| Liana Dimitrakopoulou, Investor Officer | ||
| Lucia Tweezers, VP Board | ||
| Panagiotis Pavlou, Group Director | ||
| Eleana Nikolopoulou, Group Sec | ||
| Telemaque Lavidas, Ex Director |
Lavipharm Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lavipharm a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | 0.0403 | |||
| Profit Margin | 0.02 % | |||
| Operating Margin | 0.08 % | |||
| Current Valuation | 59.98 M | |||
| Shares Outstanding | 18.29 M | |||
| Shares Owned By Insiders | 67.47 % | |||
| Price To Earning | 12.42 X | |||
| Price To Sales | 0.17 X | |||
| Revenue | 41.37 M | |||
| Gross Profit | 15.89 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Lavipharm Stock Analysis
When running Lavipharm's price analysis, check to measure Lavipharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lavipharm is operating at the current time. Most of Lavipharm's value examination focuses on studying past and present price action to predict the probability of Lavipharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lavipharm's price. Additionally, you may evaluate how the addition of Lavipharm to your portfolios can decrease your overall portfolio volatility.